A BILL 
To direct the Government Accountability Office to evaluate 
appropriate coverage of assistive technologies provided 
to patients who experience amputation or live with limb 
difference. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Access to Assistive 
4
Technology and Devices for Americans Study Act’’ or the 
5
‘‘Triple A Study Act’’. 
6
23:24 May 27, 2021
H2461
2 
•HR 2461 IH
SEC. 2. APPROPRIATE COVERAGE OF ASSISTIVE TECH-
1
NOLOGIES. 
2
(a) IN GENERAL.—Not later than 18 months after 
3
the date of enactment of this Act, the Comptroller General 
4
of the United States shall evaluate, and submit to Con-
5
gress a report on such evaluation, the appropriate cov-
6
erage, through insurance or otherwise, of assistive tech-
7
nologies provided to patients who experience amputation 
8
or live with limb difference, particularly prosthetic devices 
9
and custom orthoses, including— 
10
(1) timely access to care, including educating 
11
patients regarding options for assistive technologies; 
12
(2) assessments and guidelines for assistive de-
13
vice determinations; 
14
(3) matching specific assistive devices with the 
15
needs of the individual beneficiary, such as women; 
16
(4) the affordability of assistive devices; 
17
(5) the provision of rehabilitation services to 
18
support acclimation to assistive devices; and 
19
(6) appropriate timelines for assessments for 
20
surgery and assessments of assistive devices. 
21
(b) COMPARISON OF CERTAIN DATA.—As part of the 
22
evaluation conducted under subsection (a), the Comp-
23
troller General shall compare data on practices and out-
24
comes derived from the Medicare program under title 
25
XVIII of the Social Security Act (42 U.S.C. 1395 et seq.), 
26
23:24 May 27, 2021
H2461
3 
•HR 2461 IH
the Department of Veterans Affairs, and the commercial 
1
health insurance market relating to the coverage of assist-
2
ive technologies, including— 
3
(1) the percentage of patients who get access to 
4
assistive devices; 
5
(2) performance measures that monitor the 
6
timeliness of processing prosthetic prescriptions; 
7
(3) coverage denials and overturn rates; 
8
(4) coding for physician or physical therapy or 
9
occupational therapy assessments, including whether 
10
a prosthetist was engaged in the assessment; 
11
(5) the rate of patients returning to work in 
12
general, and after receiving a prosthetic device com-
13
parable to other assistive technologies; 
14
(6) reductions in long-term assistive technology 
15
services and supports; 
16
(7) with respect to those using assistive tech-
17
nologies, policies to reduce falls and secondary com-
18
plications, such as diabetes, heart disease, vascular 
19
disease, and others; and 
20
(8) the amount expended by individual entities 
21
on prosthetics relative to total amount expended by 
22
such entities. 
23
Æ 
23:24 May 27, 2021
H2461
